Opus Genetics (IRD) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.60% |
| Dec 31, 2025 | 3.97% |
| Sep 30, 2025 | -33.66% |
| Jun 30, 2025 | -47.82% |
| Mar 31, 2025 | -29.42% |
| Dec 31, 2024 | -57.15% |
| Sep 30, 2024 | -28.56% |
| Jun 30, 2024 | -22.75% |
| Mar 31, 2024 | -14.38% |
| Dec 31, 2023 | -1.80% |
| Sep 30, 2023 | 27.45% |
| Jun 30, 2023 | -1.50% |
| Mar 31, 2023 | -0.82% |
| Dec 31, 2022 | 55.13% |
| Sep 30, 2022 | -1.47% |
| Jun 30, 2022 | -2.88% |
| Mar 31, 2022 | -10.48% |
| Dec 31, 2021 | -9.43% |
| Sep 30, 2021 | -2.63% |
| Jun 30, 2021 | -12.77% |
| Mar 31, 2021 | -1.29% |
| Dec 31, 2020 | -26.28% |
| Sep 30, 2020 | 16.00% |
| Jun 30, 2020 | 23.51% |
| Mar 31, 2020 | 9.14% |
| Dec 31, 2019 | 26.98% |
| Sep 30, 2019 | 6.21% |
| Jun 30, 2019 | 3.16% |
| Mar 31, 2019 | -7.32% |
| Dec 31, 2018 | -16.32% |
| Sep 30, 2018 | -20.76% |
| Jun 30, 2018 | -21.19% |
| Mar 31, 2018 | -25.26% |
| Dec 31, 2017 | -36.16% |
| Sep 30, 2017 | -18.58% |
| Jun 30, 2017 | -18.30% |
| Mar 31, 2017 | -15.98% |
| Dec 31, 2016 | -10.27% |
| Sep 30, 2016 | -2.07% |
| Jun 30, 2016 | 9.54% |
| Mar 31, 2016 | -4.45% |
| Dec 31, 2015 | -6.71% |
| Sep 30, 2015 | -14.50% |
| Jun 30, 2015 | -8.61% |